2646.1000 30.30 (1.16%)
NSE Nov 18, 2026 15:31 PM
Volume: 1.1M
 

ICICI Securities Limited
Glenmark Pharmaceuticals (Glenmark)’s Q1FY27 revenue was better our estimates, although EBITDA and profits lagged expectations. Strong growth across India (+15.5% YoY), US (+8.5% YoY) and emerging markets (+27.7% YoY) drove the revenue outperformance.
Number of FII/FPI investors increased from 473 to 502 in Sep 2026 qtr.
More from Glenmark Pharmaceuticals Ltd.
Recommended